About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

NCT01123304·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Morphotek

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically confirmed AJCC Stage IIIB, IIIC or IV melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules)
Tumor accessible to intra-tumoral injections
Cumulative tumor volume great enough to accept MORAb-028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3

You may not be if

Are candidates for curative surgical excision or lymphadenectomy
Prior non-surgical treatment within 4 weeks
Known central nervous system (CNS) tumor involvement or metastases
Hypersensitivity to MORAb-028

The record

StatusTerminated

PhasePhase 1

Taking part18

StartedMay 2010

UpdatedJul 17, 2014

Conditions

Where1

John Wayne Cancer Institute
Santa Monica, California, United States